✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic ExerciseEndocannabinoid SystemPain ManagementPerformanceSafety Why This MattersExercise-induced analgesia and mood enhancement share endocannabinoid pathways with...
endocannabinoid system: Cannabis Anxiety Research 2026
Clinical Takeaway Cannabis use for anxiety produces measurable daily reductions in anxiety symptoms, but the magnitude and pattern of relief differ depending on whether flower or edible products are used. CBD-containing products...
`Endocannabinoid System Research: Cannabis for PTSD and SUD`
Clinical Takeaway People with PTSD who use cannabis can still benefit meaningfully from trauma-focused treatments, and cannabis use does not appear to significantly undermine treatment outcomes compared to non-users. This finding holds...
Endocannabinoid System Research in Athlete Mental Health
Clinical Takeaway Retired professional athletes from high contact team sports show elevated rates of depression, anxiety, and cognitive concerns compared to the general population, likely linked to cumulative head trauma, abrupt career...
endocannabinoid system clinical research: Cannabis for Back Pain
Clinical Takeaway In this phase 3 trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to...
Cannabinoids, Autophagy, and Alzheimer’s Disease, What This Review Explores and What It Still Leaves Unproven
This 2026 review explores how cannabinoids might influence autophagy pathways relevant to Alzheimer’s disease. Its value is mainly mechanistic and hypothesis-building, with some discussion of early clinical and preclinical signals. It does not prove that cannabinoids currently offer established disease-modifying treatment for Alzheimer’s disease.
Cannabis compounds reverse fatty liver disease in mice – Instagram
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Liver DiseasePreclinical ResearchMetabolismNafldEndocannabinoid System Why This MattersPreclinical studies on cannabinoids and metabolic liver disease...
Study: Clinical evidence review for Cannabidiol
This 2024 paper is a narrative review of cannabidiol, cannabis-derived products, regulation, pharmacology, and clinical use. It offers a useful overview of why purified CBD, commercial extracts, and broader cannabis products should not be treated as interchangeable. Its value is real, but it remains a narrative review, not a new trial, so its conclusions should be read as framing and synthesis rather than definitive proof.
Letter by Wu et al Regarding Article, “G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice”.
CED Clinical Relevance #56Monitored Relevance Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch | CED Clinic DiabetesCardiovascularCb2MechanismResearch JournalCirculationStudy TypeClinical StudyPopulationHuman participants Why This MattersThis mechanistic research illuminates how cannabinoid receptor 2 (CB2)...
Cannabis and Sleep: A Proposed Bidirectional Risk Cycle Built on Narrative Evidence
Sleep problems prompt self-medication with cannabis, which inadvertently maintains or worsens sleep problems due to predictable neurobiological processes. Over time, self-medication behavior may increase to compensate for cannabis tolerance and ongoing sleep problems, ultimately increasing risk for cannabis use disorder and associated consequences.